| Document |
Document Title |
|
WO/2013/027188 |
The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereo...
|
|
WO/2013/027986 |
The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use...
|
|
WO/2013/027794 |
A compound represented by formula [I] [wherein ring A represents a nitrogenated heteroaryl group which may be substituted; ring B represents an aliphatic monocyclic group which may be substituted; X1 to X5 fulfill any one of the followin...
|
|
WO/2013/026787 |
The invention relates to fluorinated fentanyl derivatives that function as opioid receptor agonists, which activate target opioid receptors in a pH-dependent manner, and are thus selective for the receptors in inflamed (acidic) milieu; u...
|
|
WO/2013/026264 |
Disclosed is a cannabinoid (CB1) acceptor inhibitor compound with nitrogen-containing aromatic ring having hydroxyl shown as general formula I and a physiologically acceptable salt and solvate thereof. Wherein each substituent definition...
|
|
WO/2013/026151 |
Stevia is a zero or low calorie natural sweetener that can be extracted from the leaves of Stevia Rebaudiana. An improved stevia rebaudiana extract is presently disclosed having low or no after-taste as well as a process for obtaining. T...
|
|
WO/2013/023439 |
The present invention relates to salts and a pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystal, anhydride or amorphous form of a novel pyrazolopyrimidinone compound as shown in general formula (I), and to a p...
|
|
WO/2013/026060 |
Methods for predicting a propensity for brain disease in a diabetic or pre-diabetic individual determining the amount and/or molecular weight of islet amyloid polypeptide (IAPP) present a sample from the individual are provided. Further ...
|
|
WO/2013/025442 |
Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium ...
|
|
WO/2013/024312 |
The invention refers to the use of an amidoxime derivative of formula I or a pharmaceutically suitable acid addition salt thereof for the preparation of a composition or pharmaceutical composition that ameliorates the tissue regeneration...
|
|
WO/2013/025474 |
The disclosure includes compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium autocrine proliferation re...
|
|
WO/2013/024898 |
The primary purpose of the present invention is to provide a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the present invention can include a heterocyclic compound represented by general formul...
|
|
WO/2013/025607 |
Embodiments of the invention include methods of using vitamin B12 to influence amyloid-beta peptide aggregation. A preferred method comprises contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta p...
|
|
WO/2013/024028 |
The present invention relates to gamma-hydroxyburyrate (GHB), or GBH derivatives or GHB structurally-related compounds, for use in the treatment of a proteinopathy.
|
|
WO/2013/024168 |
The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxym...
|
|
WO/2013/025442 |
Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium ...
|
|
WO/2013/026064 |
The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphin...
|
|
WO/2013/024474 |
The present invention provides novel crystalline forms of preladenant, pharmaceutical compositions comprising same, methods for their preparation and use thereof in treating a neurodegenerative disease, especially Parkinson's Disease (PD).
|
|
WO/2013/025425 |
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 - R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, ...
|
|
WO/2013/025474 |
|
|
WO/2013/023852 |
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia.
|
|
WO/2013/025042 |
The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis ...
|
|
WO/2013/020722 |
Compositions and methods comprising or using a combination of an amyloid beta mimotope and an adjuvant such as AS01B are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's d...
|
|
WO/2013/022139 |
Disclosed are a method for treatment of diseases caused by accumulation of β-amyloids in brain parenchyma, which includes administering a thiazolidinedione derivative represented by Formula 1 to a subject suffering from the same, so as ...
|
|
WO/2013/020723 |
Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a β-amyloid antigen are provided. The compositions and methods provided are 5 particularly useful for prevention or treatment...
|
|
WO/2013/020914 |
The invention pertains to a peptide comprising a peptide with a sequence according to SEQ ID NO 1 to 7 covalently coupled to a polyethylene glycol (PEG) molecule for treating multiple sclerosis.
|
|
WO/2013/020930 |
The present invention relates to aminochromane, aminothiochromane and 1,2,3,4-tetrahydroquinoline derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprisin...
|
|
WO/2013/023102 |
This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPAl ion channel and/or medical conditions related to TRPAl, such as pain or asthma.
|
|
WO/2013/020992 |
The present invention relates to dihydrothienopyrimidines,their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere wit...
|
|
WO/2013/023104 |
A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthr...
|
|
WO/2013/020229 |
Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of gene...
|
|
WO/2013/022079 |
The present invention provides a novel fatty acid derivative. The present invention also provides use of an effective amount of a fatty acid derivative for treating schizophrenia in a mammalian subject.
|
|
WO/2013/020440 |
Disclosed are an amide derivate represented by formula (I), and a pharmaceutically acceptable salt or solvate thereof. Also disclosed are a preparation method for the amide derivate, a pharmaceutical composition containing the amide deri...
|
|
WO/2013/022972 |
The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.
|
|
WO/2013/020722 |
Compositions and methods comprising or using a combination of an amyloid beta mimotope and an adjuvant such as AS01B are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's d...
|
|
WO/2013/021353 |
An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the pro...
|
|
WO/2013/022717 |
The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.
|
|
WO/2013/020909 |
The present invention relates to surfen and derivatives and analogues thereofand their use in prevention and treatment of tauopathies, including Alzheimer's disease. Derivatives of surfen and novel medical uses and methods relating there...
|
|
WO/2013/021196 |
The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the ...
|
|
WO/2013/020966 |
The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders.
|
|
WO/2013/020368 |
This invention relates to extract, fractions and isolated compound of Rhodiola rosea, and uses thereof for treating neuropathological and neurodegenerative diseases. The extracts and compounds of the present invention inhibit the aggrega...
|
|
WO/2013/020724 |
The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as t...
|
|
WO/2013/018372 |
[Problem] To provide a novel amide derivative having greater safety and having superior phosphodiesterase 4 inhibition. [Solution] The novel amide derivative, which is represented by general formula (1), has strong PDE 4 inhibiting activ...
|
|
WO/2013/019938 |
Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2013/020136 |
The invention teaches a method and kit for treating traumatic brain injury, concussion and/or other conditions involving brain, head/neck and/or neurological injury. Specifically, the invention teaches the use of erythropoietin and stem ...
|
|
WO/2013/018883 |
The present invention identifies a cancer antigen protein that is specifically expressed at the surface of cancer cells, and provides an antibody having the protein as a target and an application of the antibody as a cancer treatment and...
|
|
WO/2013/017071 |
Disclosed are alicyclic[c] benzopyrone derivatives and uses thereof. The said alicyclic[c] benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity ...
|
|
WO/2013/017974 |
The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions...
|
|
WO/2013/018733 |
A 1,5-naphthyridine derivative represented by general formula [1] (wherein each of R1, R2, R3, R4 and R5 represents a hydrogen atom, an -L-Z group (wherein Z represents a non-aromatic heterocyclic group or the like, and L represents a si...
|
|
WO/2013/019711 |
The invention is directed to novel 17β-heteroaryl substituted steroids of Formula I, pharmaceutical compositions thereof, and their use as modulators of GABAA receptors.
|
